NOVO INTEGRATED SCIENCES INC (NVOS)
US67011T3005 - Common Stock
Overall NVOS gets a fundamental rating of 1 out of 10. We evaluated NVOS against 109 industry peers in the Health Care Providers & Services industry. NVOS may be in some trouble as it scores bad on both profitability and health. NVOS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
NVOS had negative earnings in the past year.
NVOS had a negative operating cash flow in the past year.
NVOS had negative earnings in each of the past 5 years.
In the past 5 years NVOS always reported negative operating cash flow.
1.2 Ratios
NVOS's Return On Assets of -68.87% is on the low side compared to the rest of the industry. NVOS is outperformed by 89.47% of its industry peers.
Looking at the Return On Equity, with a value of -244.36%, NVOS is doing worse than 85.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.87% | ||
| ROE | -244.36% | ||
| ROIC | N/A |
ROA(3y)-41.58%
ROA(5y)-27.97%
ROE(3y)-70.22%
ROE(5y)-45.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVOS has a better Gross Margin (37.68%) than 67.54% of its industry peers.
In the last couple of years the Gross Margin of NVOS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NVOS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y0.48%
2. Health
2.1 Basic Checks
NVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NVOS has more shares outstanding
Compared to 5 years ago, NVOS has more shares outstanding
NVOS has a better debt/assets ratio than last year.
2.2 Solvency
NVOS has an Altman-Z score of -4.58. This is a bad value and indicates that NVOS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NVOS (-4.58) is worse than 84.21% of its industry peers.
NVOS has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.16, NVOS is doing good in the industry, outperforming 70.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.58 |
ROIC/WACCN/A
WACC7.3%
2.3 Liquidity
A Current Ratio of 0.27 indicates that NVOS may have some problems paying its short term obligations.
NVOS has a Current ratio of 0.27. This is amonst the worse of the industry: NVOS underperforms 92.98% of its industry peers.
A Quick Ratio of 0.22 indicates that NVOS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.22, NVOS is doing worse than 93.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.27 | ||
| Quick Ratio | 0.22 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 84.52% over the past year.
The Revenue has grown by 1106.87% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 7.18% on average over the past years.
EPS 1Y (TTM)84.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-635.41%
Revenue 1Y (TTM)1106.87%
Revenue growth 3Y16.95%
Revenue growth 5Y7.18%
Sales Q2Q%-4.2%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NVOS. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
NVOS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NOVO INTEGRATED SCIENCES INC
NASDAQ:NVOS (11/5/2024, 8:00:01 PM)
After market: 0.1132 -0.04 (-24.53%)0.15
-0.02 (-13.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners5.23%
Inst Owner Change-9.5%
Ins Owners1.14%
Ins Owner Change0%
Market Cap2.86M
Analysts0
Price TargetN/A
Short Float %0%
Short Ratio0
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.38
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.71
BVpS0.52
TBVpS-0.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.87% | ||
| ROE | -244.36% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.68% | ||
| FCFM | N/A |
ROA(3y)-41.58%
ROA(5y)-27.97%
ROE(3y)-70.22%
ROE(5y)-45.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y0.48%
F-Score3
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.37% | ||
| Cap/Sales | 0.23% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.27 | ||
| Quick Ratio | 0.22 | ||
| Altman-Z | -4.58 |
F-Score3
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)7.85%
Cap/Depr(5y)52.85%
Cap/Sales(3y)1.6%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-635.41%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1106.87%
Revenue growth 3Y16.95%
Revenue growth 5Y7.18%
Sales Q2Q%-4.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.83%
OCF growth 3YN/A
OCF growth 5YN/A